Skip to content

Non-invasive Transcranial Focused Low-intensity Ultrasound Stimulation in Patients With Mild Lewy Body Dementia

Clinical Single-center Randomized Controlled Trial of Non-invasive Transcranial Focused Low-intensity Ultrasound Stimulation in Patients With Mild Lewy Body Dementia

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05499429
Acronym
tFUS in DLB
Enrollment
20
Registered
2022-08-12
Start date
2022-09-30
Completion date
2026-11-30
Last updated
2022-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lewy Body Dementia

Brief summary

A randomized controlled clinical study was conducted in the xuanwu hospital Single Center of Capital Medical University to preliminarily explore the efficacy and safety of transcranial focused low-intensity ultrasound stimulation in the treatment of dementia with Lewy bodies in the early stage, to clarify the effective mechanism and form an effective clinical treatment plan.

Detailed description

This project plans to recruit 20 patients with mild Lewy body dementia.They were randomly divided into transcranial focused low-intensity ultrasound active stimulation group and sham stimulation group. Patients receive treatment three days a week, and the daily treatment time is 20-30 minutes.The duration of treatment is 4-12 weeks. Before treatment, cognitive assessment, resting EEG, head MRI and PET examination of glucose metabolism were completed.Complete the overall cognitive assessment, resting EEG and MRI examination within one week after the treatment, and complete the overall cognitive assessment and PET examination of glucose metabolism at the follow-up 6 months after the treatment.Fill in the treatment side effect scale and adverse event form.Keep the original oral drug dosage unchanged during the treatment process.

Interventions

DEVICETranscranial low intensity focused ultrasound stimulation

Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.

Sponsors

Xuanwu Hospital, Beijing
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Patients were randomly assigned to the active stimulation group and sham stimulation group, Patients,Care Provider and Outcomes Assessor did not know the patient grouping.

Intervention model description

Patients were randomly assigned to the active stimulation group and sham stimulation group.

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Male or female DLB patients between the ages of 50-85; * The psychological evaluation was in accordance with MMSE score of 18-24 (including 18 and 24) and CDR score of 0.5. * Can cooperate to complete clinical research.

Exclusion criteria

* There is a definite history of cerebrovascular stroke, and there are definite symptoms or signs of neurological deficit at the time of onset, and there are corresponding responsible lesions left by neuroimaging。 * Those who have a history of alcoholism, or drug addiction, or neurological diseases such as brain trauma, epilepsy, encephalitis, normal intracranial pressure hydrocephalus, etc. that can cause cognitive impairment. * Suffering from systemic diseases that may lead to cognitive impairment (such as liver and kidney insufficiency, endocrine diseases, vitamin deficiency). * Have a history of using antipsychotics for more than five years before diagnosis. * There are contraindications for head MRI examination.

Design outcomes

Primary

MeasureTime frameDescription
Clinical Global Impression Scale12 weeksEvaluate the improvement of clinical symptoms.

Secondary

MeasureTime frameDescription
resting EEG12 weeksEEG power in alpha band
head MRI12 weeksChanges of brain function by fMRI

Countries

China

Contacts

Primary ContactPenghu Wei, doctor
weipenghu@xwhosp.org18601986863

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026